Methods of antibiotic bonding to vascular prostheses
DOI:
https://doi.org/10.12923/Keywords:
vascular prostheses, antibiotics immobilization, antibacterial prostheses protectionAbstract
Besides autogenous implantable materials, synthetic vascular prostheses made of synthetic polymeric biomaterials are frequently used in surgical vessel reconstructions. The important problems appearing while using these types of biomaterials are postoperative infections, which may repeatedly lead to limb amputation or even patient’s death. Presently, in order to avoid the postoperative infections, prostheses are soaked in an appropriate antibiotic solution to obtain weak adsorptive or ionic interactions. Moreover, new methods of antibiotic bonding to biomaterials by strong covalent immobilization are investigated. This work is a short review of the presently known methods of antibiotics bonding.
References
1. Avramovic J.R., Fletcher J.R.: Rifampicin impregnation of a protein-sealed Dacron graft: an infection reistant vascular graft. Aust. N.Z. J. Surg., 61, 436, 1991.
2. Bandyk F.D., Novotney M.L., Back M.R., Johnson B.L., Schmacht D.C.: Expanded application of in situ replacement for prosthetic graft infection. J. Vasc. Surg., 34, 411, 2001.
3. Begovac P.C., Thomson R.C., Fisher J.L., Hughson A., Gallhagen A.: Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. Eur. J. Vasc. Endovasc. Surg. 25, 432, 2003.
4. Belt H, Neut D, Schenke W, Horn JR, der Mei HC, Busschner HJ.: Staphylococcus aureus biofilm formation on different gentamicin-loaded poly (methyl methacrylate) bone cements. Biomaterials; 22, 1607, 2001.
5. Blanchemain N., Haulon S., Martel B., Traisnel M., Morcellet M., Hildebrand H.F.: Vascular PET prostheses surface modification with cyclodextrin coating: development of a new drug delivery system. Eur. J. Vasc. Endovasc. Surg. 29, 628, 2005.
6. Blanchemain N., Karrout Y., Tabary N., Neut C., Brita M., Siepmann J., Hildebrand H.F., Martel B.: Methyl-β-cyclodextrin modified vascular prosthesis: Influence of the modification level on the drug delivery properties in different media. Acta Biomater. 7, 304, 2011.
7. Cirioni O., Mocchegiani R., Ghiselli C., Silvestri E., Gabrielli E., Marchionni E., Orlando F., Nicolini D., Risaliti A., Giacometti A. Daptomycin and Rifampin alone and in combination prevent vascular graft biofilm formation and emergencje of antibiotic resistance in a subcutaneous rat pouch model of Staphylococcal infection. Eur. J. Vasc. Endovasc. Surg. 40, 817, 2010
8. Clark R.E. i Margraf H.W.: Antibacterial vascular grafts with improved thromboresistance. Arch. Surg., 109, 159, 1974.
9. Dahn M.S.: What’s new in vascular infections? Mini-symposium. Current Surgery 56, (6), 335, 1999.
10. Earnshaw J.J.: The current role of rifampicin-impregnated grafts: Pragmatism versus science. Eur. J. Vasc. Endovasc. Surg., 20, 409, 2000.
11. Fischer P.E., Schroeppel T.J., Fabian T.C., deRijk W. G., Edwards N.M., Magnotti L.J., Doty D. H., Croce M.A. Antibiotic-coated ePTFE decreases graft colonization and neointimal hyperplasia. J. Surg. Res. 156, 199, 2009.
12. Gahtan V., Esses G.E., Bandyk D.F., Nelson R.T., Dupont E., Mills J.L.: Antistaphylococcal activity of rifampin-bonded gelatin impregnated Dacron prosthesis. J. Surg. Res.; 58, 105, 1995.
13. Ginalska G., Kowalczuk D., Osińska M.: A chemical method of gentamicin bonding to gelatine-sealed prosthetic vascular grafts. Int. J. Pharm., 288, 131, 2005.
14. Ginalska G., Osińska M., Uryniak A.: A Covalent method of gentamicin bonding to silica supports. J. Biomater. Applic., 18, (4), 279, 2004.
15. Goëau-Brissonnière O., Mercier F., Nicolas M.H., Bacourt F., Coggia M., Lebrault C., Pechère J.C.: Treatment of vascular graft infection by in situ replacement with a rifampin-bonded gelatin-sealed Dacron graft. J. Vasc. Surg., 19, 739, 1994.
16. Haverich A, Hirt S, Karak M, Sialan F, Wahling H. Prevention of graft infection by bonding gentamicin to Dacron prostheses. J. Vasc. Surg; 15, 187, 1998.
17. Heise M., Schmidmaier G., Husmann I., Heidenhain C., Schmidt J., Neuhaus P., Settmacher U. PEG-hirudin/iloprost coating of small diameter ePTFE graft effectively prevents pseudointima and intimal hyperlasia development. Eur. J. Vasc. Endovasc. Surg. 32, 418, 2006.
18. Homer-Vanniasinkam S.: Surgical site and vascular infections: treatment and prophylaxis. Int. J. Infect. Dis., 24, 283, 2002.
19. Janczak D., Pupka A., Skóra J., Szyber P., Czapla B. The use of the heparyn-bonded e PTFE grafts for needs of the hemodialisis. Polimery w Medycynie 4, 40, 2010.
20. Kempczinski R.F.: Discussion following Moore i wsp. Development of an infection-resistant vascular prosthesis. Discussion at 29th Scientific Meeting of the International Cardiovascular Society. North Amer., Chapter, Dallas, Arch. Surg., 116, 1407, 1981.
21. Kinney E.V., Bandyk D.F., Seabrook G.A., Kelly H.M., Towne J.B.: Antibiotic-bonded PTFE vascular grafts: the effect of silver antibiotic on bioactivity following implantation. J. Surg. Res., 50, 430, 1991.
22. Kocsis J.F., Llanos G., Holmer E.: Heparyn-coated stents. J. Long. Term. Elf. Med. Implants 10, 19, 2000.
23. Kuehn Ch., Graf K., Mashaqi B., Pichlmaier M., Heter W., Hilfiker A., Stiesch M., Chaberny I.F., Haverich A. Prevention of early vascular graft infection using regional antibiotic release J. Surg. Res. 164, e185, 2010.
24. Lyczak J.B., Cannon C.I., Pier G.B.: Establishment of Pseudomonas aeruginosa infection: lesions from a versatile opportunist. Microbe. Infect., 2, 1051, 2000.
25. Mc Dougal E.G., Burnham S.J., Johnson G. Jr.: Rifampicin protection against experimental graft sepsis. J. Vasc. Surg,. 4, 5, 1986.
26. Powell T.W., Burnham S.J., Johanson G.: A passive system using Rifampicin to create on infection-resistant vascular prosthesis. Surgery 94, 765, 1983.
27. Riesenfeld J., Olsson P., Sanchez J., Mollnes T.E.: Surface modification with functionally active heparyn. Med. Device Technol. 6, 24, 1995
28. Shue W.B., Worosilo S.C., Donetz A.P., Trooskin S.Z., Harvey R.A., Greco R.S.: Prevention of vascular prosthetic infection with an antibiotic-bonded Dacron graft. J. Vasc. Surg., 8, 600, 1988.
29. Sobinsky K.R. i Flanigan D.P.: Antibiotic binding to polytetrafluroethylene via glucosoaminoglycan – keratin luminal coating. Surgery 100, 629, 1986.
30. Strachan C.J.L., Newsom S.W.B., Ashton T.R.: The clinical use of an antibiotic-bonded graft. Eur. J. Vasc. Surg., 5, 627, 1991.
31. Valentine J.R.: Diagnosis and management of graft infection. Seminars in vascular Surgery 14, 292, 2001.
32. Vicaretti M., Hawthorne W.J., Ao P.Y., Fletcher J.P.: An increased concentration of rifampicin bonded to gelatin-sealed Dacron reduces the incidence subsequent graft infection following a staphylococcal challenge. Cardiovasc. Surg., 6, 268, 1998.
33. Walluscheck K.P., Bierkandt M., Brandt J., Cremer J. Infrainguinal ePTFE vascular graft with bioactive surface heparin bonding. J. Cardiovasc. Surg. 46, 425, 2005.
34. Wang H.Y., Ren C.J., Zhang Y.C.: Use of p-dimethylaminobenzaldehyde as a coloured reagent for determination of gentamycin. Talanta 40, 851, 1993.
35. Wipke-Tevis D.D.: Vascular infections: medical and surgical therapies. J. Cardiovasc. Nurs., 13, 70, 1999.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
